Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma

Cancer Res. 2022 Jul 5;82(13):2403-2416. doi: 10.1158/0008-5472.CAN-21-2352.

Shawn M Davidson^{1

2

3}, Daniel R Schmidt^#^{1

3

4}, Julia E Heyman^#¹, James P O'Brien^#¹, Amy C Liu^#¹, William J Israelsen^{1

2}, Talya L Dayton^{1

2}, Raghav Sehgal⁵, Roderick T Bronson¹, Elizaveta Freinkman⁶, Howard H Mak¹, Giuseppe Nicolò Fanelli^{7

8}, Scott Malstrom¹, Gary Bellinger^{1

4}, Arkaitz Carracedo⁴, Pier Paolo Pandolfi⁴, Kevin D Courtney⁹, Abhishek Jha⁵, Ronald A DePinho⁹, James W Horner⁹, Craig J Thomas¹⁰, Lewis C Cantley^{4

7}, Massimo Loda^{7

9}, Matthew G Vander Heiden^{1

2

3

9}

¹ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
² Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
³ Broad Institute of MIT and Harvard University, Cambridge, Massachusetts.
⁴ Beth Israel Deaconess Medical Center, Boston, Massachusetts.
⁵ Elucidata, Cambridge, Massachusetts.
⁶ Whitehead Institute, Cambridge, Massachusetts.
⁷ Weill Cornell Medical College, New York, New York.
⁸ Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
⁹ Dana-Farber Cancer Institute, Boston, Massachusetts.
¹⁰ National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland.

^# Contributed equally.

Abstract

Differential expression of PKM1 and PKM2 impacts prostate tumorigenesis and suggests a potential therapeutic vulnerability in prostate cancer.